MedPath

Impact of a Group Intervention on Breast Cancer Patient's Adjustment and Emotion Regulation at the End of Treatment

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Behavioral: Cognitive-behavioral therapy and hypnosis group
Behavioral: Support group
Registration Number
NCT01797354
Lead Sponsor
Université Libre de Bruxelles
Brief Summary

Background: The end of treatment is for cancer patients the beginning of a critical rehabilitation period including numerous physical, emotional, professional and cognitive challenges. Specific interventions adapted to this post-treatment period need thus to be designed. Interventions such as group cognitive-behavioral therapy and hypnosis have been shown to be effective. However, moderate effect sizes, no comprehensive description of the treatment interventions and assessments relying only on self-report measures warrant further investigation. This study aims to assess, in breast cancer patients at the end of treatment, the impact of a group intervention combining cognitive-behavioral therapy and hypnosis versus a group intervention on patient's adjustment and emotion self-regulation.

Design: This is a two-armed, longitudinal, randomized controlled trial. Breast cancer patients finishing their radiation therapy treatment will be randomized to either an immediate group intervention combining cognitive-behavioral therapy and hypnosis or a group intervention. Patients will be assessed at three time points during the first year following the end of treatment: at 1 (T1), 6 (T2) and 12 (T3) months after the end of treatment. Patients' adjustment will be assessed through questionnaires. Patient emotion self-regulation ability will be assessed through their ability to respond both subjectively (self-reported emotional state) and objectively (heart rate) to two emotion self-regulation tasks.

Discussion: It is hypothesized that a group intervention combining cognitive-behavioral therapy and hypnosis will be more effective than a group intervention. Results of this study will contribute to improving post-treatment care for breast cancer patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
260
Inclusion Criteria
  • Non-metastatic breast cancer (in situ or invesive)
  • End of active treatments (surgery, chemotherapy and radiotherapy)
  • No recurrence nor palliative care
  • Min. 18 years
  • Able to speak French
  • Willing to be randomized to study intervention group
  • Accept to give their written informed consent
Exclusion Criteria
  • No cognitive dysfunction
  • No severe or uncontrolled psychiatric illness

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Cognitive-behavioral therapy and hypnosis groupCognitive-behavioral therapy and hypnosis groupPatients will receive (in groups of 6) fifteen 120-min sessions of group therapy including cognitive-behavioral techniques and hypnosis.
Support groupSupport groupPatients will receive (in groups of 6) fifteen 120-min support group session.
Primary Outcome Measures
NameTimeMethod
Psychological wellbeing: emotional state, emotional adjustment, social adjustment, quality of life,...Change from baseline in emotional state, emotional adjustment, social adjustment and quality of life at 6 (T1) and 12 (T2) months.

Questionnaires:

* the Hospital Anxiety and Depression Scale

* the Rosenberg's Self-Esteem

* the Mental Adjustment to Cancer Scale

* the Fear of Cancer Recurrence Inventory

* the Perceived Social Support Questionnaire

* the Courtauld Emotional Control scale

* the Ways of Coping Checklist

* the Toronto Alexithymia Scale

* a questionnaire about usual emotional state

* a questionnaire about the use of relaxation techniques and self-hypnosis

Physical wellbeing: emotion regulation ability (heart rate, relaxation, quality of life,...)Change from baseline in heart rate and relaxation ability at 6 (T2) and 12 months (T3)

Questionnaires:

* Quality of life questionnaires: "EORTC QLQ-C30" and "EORTC-BR23"

* Edmonton symptom evaluation scale

* Way of life questionnaire

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Institut Jules Bordet

🇧🇪

Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath